Radioligand Therapy with 177Lu-PSMA-617 in Patients with Diffuse Bone Marrow Involvement: Safety and Efficacy Results

Conclusion: RLT with 177Lu-PSMA-617 in patients with diffuse bone marrow involvement can be performed with an acceptable risk profile and may contribute to prolonged disease control. Diffuse bone marrow involvement should therefore not routinely be considered an exclusion criterion for RLT.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Groner, D., Nguyen Ngoc, C., Davis, K., Happel, C., Baumgarten, J., Banek, S., Mandel, P., Gruenwald, F., Sabet, A. Tags: GU - Radioligand Therapy (Poster Session) Source Type: research